腺癌
医学
肺
癌症研究
突变
肺癌
抗药性
肺腺癌
机制(生物学)
肿瘤科
后天抵抗
内科学
靶向治疗
药品
病理
人肺
细胞
化疗
作者
H R Chen,Z Y Huang,Z R Ren,C Lu,Y Z Ding,Q Q Yu,L F Lu,S D Cang,Q Y Liu
出处
期刊:PubMed
[National Institutes of Health]
日期:2026-05-08
卷期号:55 (5): 456-461
标识
DOI:10.3760/cma.j.cn112151-20250911-00609
摘要
Lung adenocarcinomas with PIK3CA mutations exhibit distinct clinicopathological characteristics in terms of gender, age, smoking history, differentiation degree, and clinical stage. Acquired drug resistance in lung adenocarcinoma may be accompanied by PIK3CA mutations, but PIK3CA mutation is not the main mechanism of targeted therapy resistance in lung adenocarcinoma patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI